I am a physician-scientist studying immunity in cancers. T cell-based immunotherapies in the form of checkpoint blockades and cell therapies have revolutionized how we treat cancers. These agents are not uniformly effective for all patients and the durability of these responses are not equal either. The biological processes that determine the responses to immunotherapy are dependent on both T cell intrinsic processes and the tumor microenvironment. Presently, I am studying the role of the tumor microenvironment in shaping anti-tumor T cell immunity.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Arnab Ghosh discloses the following relationships and financial interests:
Ownership / Equity Interests
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.